Challenges for a Universal Staphylococcus aureus Vaccine
This review considers the reasons why the staphylococcal vaccine trials may have failed, based on new information about protective immunity against Staphylococcus aureus. The clinical trials and future vaccine candidate antigens are reviewed. Challenges facing the development of a universal S. aureu...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2012-04, Vol.54 (8), p.1179-1186 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1186 |
|---|---|
| container_issue | 8 |
| container_start_page | 1179 |
| container_title | Clinical infectious diseases |
| container_volume | 54 |
| creator | Proctor, Richard A. |
| description | This review considers the reasons why the staphylococcal vaccine trials may have failed, based on new information about protective immunity against Staphylococcus aureus. The clinical trials and future vaccine candidate antigens are reviewed. Challenges facing the development of a universal S. aureus vaccine are also considered. The lack of a biomarker that is able to predict protection is a major stumbling block in the development of a staphylococcal vaccine. The major new information involves the role of cell-mediated immunity, specifically T-helper 17 cells and interleukin 17, as well as the lack of protection afforded by specific antibodies. This has major implications for future vaccine development and planning of clinical trials. |
| doi_str_mv | 10.1093/cid/cis033 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_940835440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>23213030</jstor_id><oup_id>10.1093/cid/cis033</oup_id><sourcerecordid>23213030</sourcerecordid><originalsourceid>FETCH-LOGICAL-j220t-ad80fb431b7a4472ed410e0535fe9ff90fec2268999d7d1dbf29b2ad7e2a33c83</originalsourceid><addsrcrecordid>eNpdkMtLw0AQxhdRbK1evCsBEU_R2UeS3aMUX1DwoPW6bPZhE9JszSZC_3tXUhVkGL6B-fEx8yF0iuEag6A3ujKxA1C6h6Y4o0WaZwLvxxkynjJO-QQdhVADYMwhO0QTQmjGBGFTxOcr1TS2fbchcb5LVLJsq0_bBdUkL73arLaN117rISRq6GyUN6V11dpjdOBUE-zJTmdoeX_3On9MF88PT_PbRVoTAn2qDAdXMorLQjFWEGsYBgsZzZwVzglwVhOScyGEKQw2pSOiJMoUlihKNaczdDX6bjr_MdjQy3UVtG0a1Vo_BCkY8PgMg0he_CNrP3RtPE5iIHnBOGN5pM531FCurZGbrlqrbit_IonA5Qj4YfO7xSC_o5YxajlGHbmzkatD77s_H0owhVhfFkF3mQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026748446</pqid></control><display><type>article</type><title>Challenges for a Universal Staphylococcus aureus Vaccine</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Proctor, Richard A.</creator><creatorcontrib>Proctor, Richard A.</creatorcontrib><description>This review considers the reasons why the staphylococcal vaccine trials may have failed, based on new information about protective immunity against Staphylococcus aureus. The clinical trials and future vaccine candidate antigens are reviewed. Challenges facing the development of a universal S. aureus vaccine are also considered. The lack of a biomarker that is able to predict protection is a major stumbling block in the development of a staphylococcal vaccine. The major new information involves the role of cell-mediated immunity, specifically T-helper 17 cells and interleukin 17, as well as the lack of protection afforded by specific antibodies. This has major implications for future vaccine development and planning of clinical trials.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cis033</identifier><identifier>PMID: 22354924</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Antibodies ; Antibodies, Bacterial - immunology ; Antigens ; B lymphocytes ; Biomarkers ; Cells ; CLINICAL PRACTICE ; Clinical trials ; Clinical Trials as Topic ; Humans ; Immunity ; Immunology ; Infections ; Interleukin-17 - immunology ; Mice ; Neutrophils ; Staphylococcal Infections - prevention & control ; Staphylococcal Infections - therapy ; Staphylococcal Vaccines - administration & dosage ; Staphylococcal Vaccines - immunology ; Staphylococcus aureus ; Staphylococcus aureus - immunology ; Staphylococcus infections ; T lymphocytes ; Th17 Cells - immunology ; Treatment Failure ; Vaccination ; Vaccines</subject><ispartof>Clinical infectious diseases, 2012-04, Vol.54 (8), p.1179-1186</ispartof><rights>Copyright © 2012 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. 2012</rights><rights>Copyright University of Chicago, acting through its Press Apr 15, 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23213030$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23213030$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,1584,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22354924$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Proctor, Richard A.</creatorcontrib><title>Challenges for a Universal Staphylococcus aureus Vaccine</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>This review considers the reasons why the staphylococcal vaccine trials may have failed, based on new information about protective immunity against Staphylococcus aureus. The clinical trials and future vaccine candidate antigens are reviewed. Challenges facing the development of a universal S. aureus vaccine are also considered. The lack of a biomarker that is able to predict protection is a major stumbling block in the development of a staphylococcal vaccine. The major new information involves the role of cell-mediated immunity, specifically T-helper 17 cells and interleukin 17, as well as the lack of protection afforded by specific antibodies. This has major implications for future vaccine development and planning of clinical trials.</description><subject>Antibodies</subject><subject>Antibodies, Bacterial - immunology</subject><subject>Antigens</subject><subject>B lymphocytes</subject><subject>Biomarkers</subject><subject>Cells</subject><subject>CLINICAL PRACTICE</subject><subject>Clinical trials</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunology</subject><subject>Infections</subject><subject>Interleukin-17 - immunology</subject><subject>Mice</subject><subject>Neutrophils</subject><subject>Staphylococcal Infections - prevention & control</subject><subject>Staphylococcal Infections - therapy</subject><subject>Staphylococcal Vaccines - administration & dosage</subject><subject>Staphylococcal Vaccines - immunology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - immunology</subject><subject>Staphylococcus infections</subject><subject>T lymphocytes</subject><subject>Th17 Cells - immunology</subject><subject>Treatment Failure</subject><subject>Vaccination</subject><subject>Vaccines</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkMtLw0AQxhdRbK1evCsBEU_R2UeS3aMUX1DwoPW6bPZhE9JszSZC_3tXUhVkGL6B-fEx8yF0iuEag6A3ujKxA1C6h6Y4o0WaZwLvxxkynjJO-QQdhVADYMwhO0QTQmjGBGFTxOcr1TS2fbchcb5LVLJsq0_bBdUkL73arLaN117rISRq6GyUN6V11dpjdOBUE-zJTmdoeX_3On9MF88PT_PbRVoTAn2qDAdXMorLQjFWEGsYBgsZzZwVzglwVhOScyGEKQw2pSOiJMoUlihKNaczdDX6bjr_MdjQy3UVtG0a1Vo_BCkY8PgMg0he_CNrP3RtPE5iIHnBOGN5pM531FCurZGbrlqrbit_IonA5Qj4YfO7xSC_o5YxajlGHbmzkatD77s_H0owhVhfFkF3mQ</recordid><startdate>20120415</startdate><enddate>20120415</enddate><creator>Proctor, Richard A.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20120415</creationdate><title>Challenges for a Universal Staphylococcus aureus Vaccine</title><author>Proctor, Richard A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j220t-ad80fb431b7a4472ed410e0535fe9ff90fec2268999d7d1dbf29b2ad7e2a33c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antibodies</topic><topic>Antibodies, Bacterial - immunology</topic><topic>Antigens</topic><topic>B lymphocytes</topic><topic>Biomarkers</topic><topic>Cells</topic><topic>CLINICAL PRACTICE</topic><topic>Clinical trials</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunology</topic><topic>Infections</topic><topic>Interleukin-17 - immunology</topic><topic>Mice</topic><topic>Neutrophils</topic><topic>Staphylococcal Infections - prevention & control</topic><topic>Staphylococcal Infections - therapy</topic><topic>Staphylococcal Vaccines - administration & dosage</topic><topic>Staphylococcal Vaccines - immunology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - immunology</topic><topic>Staphylococcus infections</topic><topic>T lymphocytes</topic><topic>Th17 Cells - immunology</topic><topic>Treatment Failure</topic><topic>Vaccination</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Proctor, Richard A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Proctor, Richard A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Challenges for a Universal Staphylococcus aureus Vaccine</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2012-04-15</date><risdate>2012</risdate><volume>54</volume><issue>8</issue><spage>1179</spage><epage>1186</epage><pages>1179-1186</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>This review considers the reasons why the staphylococcal vaccine trials may have failed, based on new information about protective immunity against Staphylococcus aureus. The clinical trials and future vaccine candidate antigens are reviewed. Challenges facing the development of a universal S. aureus vaccine are also considered. The lack of a biomarker that is able to predict protection is a major stumbling block in the development of a staphylococcal vaccine. The major new information involves the role of cell-mediated immunity, specifically T-helper 17 cells and interleukin 17, as well as the lack of protection afforded by specific antibodies. This has major implications for future vaccine development and planning of clinical trials.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>22354924</pmid><doi>10.1093/cid/cis033</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2012-04, Vol.54 (8), p.1179-1186 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_940835440 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibodies Antibodies, Bacterial - immunology Antigens B lymphocytes Biomarkers Cells CLINICAL PRACTICE Clinical trials Clinical Trials as Topic Humans Immunity Immunology Infections Interleukin-17 - immunology Mice Neutrophils Staphylococcal Infections - prevention & control Staphylococcal Infections - therapy Staphylococcal Vaccines - administration & dosage Staphylococcal Vaccines - immunology Staphylococcus aureus Staphylococcus aureus - immunology Staphylococcus infections T lymphocytes Th17 Cells - immunology Treatment Failure Vaccination Vaccines |
| title | Challenges for a Universal Staphylococcus aureus Vaccine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A22%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Challenges%20for%20a%20Universal%20Staphylococcus%20aureus%20Vaccine&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Proctor,%20Richard%20A.&rft.date=2012-04-15&rft.volume=54&rft.issue=8&rft.spage=1179&rft.epage=1186&rft.pages=1179-1186&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/cis033&rft_dat=%3Cjstor_proqu%3E23213030%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026748446&rft_id=info:pmid/22354924&rft_jstor_id=23213030&rft_oup_id=10.1093/cid/cis033&rfr_iscdi=true |